Abiopharma

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

New Form 425 - NLS Pharmaceutics Ltd. Filed: 2025-09-04 AccNo: 0001213900-25-084283 Size: 71 KB

New Form 6-K - NLS Pharmaceutics Ltd. Filed: 2025-09-04 AccNo: 0001213900-25-084281 Size: 71 KB

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones

Tenon® Medical Announces Second Peer-Reviewed Catamaran Mainsail™ Study Publication, Underscores Robust and Sustainable Clinical Outcomes Out to 12 Months

Gilead - Gilead Sciences Launches Choose U™Campaign Spotlighting the Inspiring Experiences of People Living with HIV

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease

IceCures ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease